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Introduction 
As put forward in recent guidelines, the goals of treatment 
in chronic obstructive pulmonary disease (COPD) are not 
only to optimize lung function, but primarily to reduce 
symptoms and prevent exacerbations, thus increasing 
activities of daily living and improving quality of life (1). 
This overall goal needs to be borne in mind when 
evaluating the effect of different treatment modalities in 
COPD, and the effect of bronchodilators in particular. A 
key diagnostic feature of COPD is poor reversibility of 
airflow limitation following inhaled short-acting &ago- 
nists. Thus, if the effects of treatment with &agonists in 
COPD were to be evaluated merely by the improvement in 
FEVi the results, not surprisingly, would seem rather 
disappointing. Several studies have, however, indicated that 
there may be a poorer correlation between baseline forced 
expiratory volume in 1 set (FEVi) and exercise tolerance or 
health related quality of life (HRQL) in COPD than in 
asthma (2-4). Bestall et al., for example, in a group of 
patients with severe COPD, showed a clear correlation 
between exercise tolerance evaluated by walking distance, 
and disability due to dyspnoea rated according to the 
Medical Research Council (MRC) scale. Both parameters 
also correlated with HRQL, but not with baseline FEVi (2). 
Therefore, when evaluating the therapeutic potential of any 
compound, and &agonists in particular, it is important to 
consider a range of outcome measures, including not only 
FEVi, but also symptoms, exercise tolerance, exacerbation 
rates and progression of the disease demonstrated by the 
decline in FEVi. 
Effect on baseline FEVl and 
symptoms 
Single-dose studies have demonstrated a similar broncho- 
dilating effect of formoterol and salmeterol in COPD. In 
comparison to short-acting inhaled &agonists and anti- 
cholinergics, the maximal increase is very similar, but the 
effect obviously lasts longer ($6). Longer-term studies, in 
which patients were treated twice daily with a long-acting 
inhaled &agonist, have confirmed that this bronchodilat- 
ing effect is maintained. 
In the study by Boyd et al., salmeterol, 50 or 1OOpg b.i.d., 
was added to existing treatment for 4 months in 674 COPD 
patients with a mean baseline FEVi of 1.3 1. Salmeterol at 
either dose offered a maintained 7% improvement in FEVi 
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from baseline, equivalent to approximately 80 ml (7). In the 
study by Wadbo et al., which included 183 COPD patients 
with a mean baseline FEVi of 0.92 1 (34% of predicted), the 
reversibility of FEVi in response to formoterol, 27 pg, was 
less than 12% of predicted (8). Over a 3-month treatment 
period, there was an improvement of 13% in FEVi from 
baseline following formoterol Turbuhalera, 18 pg b.i.d., 
compared with placebo (8). In both studies, the broncho- 
dilating effect was maintained throughout the treatment 
period, and no signs of tolerance were seen. This is in 
agreement with observations in asthma which have 
indicated that, though long-term use of a long-acting /?2- 
agonist may result in some tolerance to the bronchopro- 
tective effect (the clinical significance of which is debated), 
the bronchodilating effect persists (9). 
Irrespective of the effect on baseline FEVi, long-term 
treatment with formoterol or salmeterol also improves 
symptoms and increases HRQL in COPD. Using a cross- 
over study design, Suppli-Ulrik showed that, in 63 COPD 
patients, treatment with salmeterol for 4 weeks had a 
significant effect both on daytime and night-time symptom 
scores, but did not improve FEVi (10). Similarly, Jones et 
al. found that salmeterol, 5Opg b.i.d:, improved HRQL in 
283 patients assessed using the Saint George’s Respiratory 
Questionnaire without increasing FEVi significantly. When 
the salmeterol dose was increased to lOOpg, the gain in 
HRQL was lost, probably due to an increase in the 
incidence of side-effects, such as tremor, which reduces the 
sense of well-being in patients (11). Again, using the same 
questionnaire, treatment with formoterol, 12pg b.i.d. for 12 
weeks, has also been shown to offer clinically significant 
improvement in HRQL (12). 
It should be emphasized that the apparent discrepancy 
between the relatively weak effect on baseline lung function, 
expressed as FEVi, and the significant and clinically 
relevant effect on symptoms and HRQL, is probably at 
least partly related to the choice of FEVi as a measure of 
airway calibre. It is generally accepted that the sensation of 
dyspnoea in COPD is mainly caused by hyperinflation, due 
to the collapse of the small airways and the consequent 
increase in the work of breathing. This hyperinflation is 
predominantly apparent during exercise. Spirometry is a 
forced expiratory manoeuvre and, thus, enhances early 
airway collapse. Non-forced pulmonary function tests, such 
as airway resistance, may therefore be more appropriate to 
quantify the degree of bronchodilatation obtained at the 
level of the small airways, which constitutes the major site 
of airflow limitation in COPD (13). Indeed, there is a better 
correlation between non-forced pulmonary function tests 
0 2000 HARCOURT PUBLISHERS LTD 
52 J. KIPS 
and symptom improvement than forced expiration tests 
when evaluating treatment in COPD (14). A recent study 
evaluated the effect of formoterol, 4.5 or 18 ,ug delivered as 
a dry powder via Turbuhaler@, on FEVi as well as airway 
resistance in a group of 12 COPD patients with a mean 
FEVi of 47% (1.3861). Reversibility to terbutaline, 1 mg, 
was 5.1% of predicted. The highest dose of formoterol 
induced a significant increase in FEVi (200ml), but both 
doses had a clearly more pronounced effect on airway 
resistance (15). 
The pharmacological properties of formoterol differ from 
those of salmeterol. Although the duration of action of 
inhaled formoterol is similar to that of salmeterol, its onset 
of action is faster and very similar to short-acting agents, 
such as salbutamol (16). It is therefore possible that 
formoterol could be used not only as maintenance 
treatment, but also on an ‘as needed’ basis for the relief 
of symptoms. This approach has the added advantage of 
reducing the number of inhalers required and thus 
simplifying the treatment regimen for the patient. So far, 
this possibility has mainly been addressed in asthma. 
Preliminary data indicate that the use of formoterol as 
rescue medication is as safe as short-acting inhaled p2- 
agonists, and at least as effective (17). Similar results seem 
very likely in COPD patients, but this issue remains to be 
specifically addressed. 
Effect on exercise tolerance 
A clinically important outcome measure for COPD patients 
is exercise performance and breathlessness on exercise. 
Again, previous studies have shown no correlation between 
the effect of treatment on these parameters and changes in 
FEVi or vital capacity. Hay et al., for example, showed that 
inhalation of an anticholinergic agent, oxitropium, sig- 
nificantly increased the 6-min walking distance and reduced 
breathlessness, assessed by the Borg scale, in comparison 
with placebo (18); this was not correlated to the effect on 
FEVi. Similarly, short-acting inhaled &agonists have been 
shown to reduce dynamic hyperinflation during exercise, 
thus improving breathlessness on exertion (14). In a recent 
study, the effect of l-week of treatment with formotero14.5, 
9 or 18 pg b.i.d., on exercise capacity was compared with 
that of ipratropium bromide, 80 pg t.i.d., or placebo using a 
bicycle ergometer test. All three doses of formoterol 
significantly prolonged the time to exhaustion, which was 
comparable to the effect of ipratropium, 8Opg t.i.d. The 
maximum Borg dyspnoea scale was unaffected (19). 
Comparable data were reported by Patakas et al., who 
evaluated the effect of salmeterol in a treadmill exercise test 
w9. 
These studies indicate that treatment with long-acting 
inhaled &agonists in COPD improves baseline lung 
function, reduces symptoms, increases exercise tolerance 
and therefore has a positive effect on the overall HRQL. 
Overall, these effects seem to be of a similar magnitude to 
those obtained with anticholinergic agents (8,19). In 
addition, at the doses normally recommended, long-acting 
inhaled /&agonists appear to be at least as safe as 
anticholinergic agents in COPD. In the comparative study 
by Wadbo et al., there was no difference in the incidence of 
adverse events in the group treated with formoterol, 18 pg 
b.i.d., and that treated with ipratropium bromide, 8Opg 
t.i.d. (8). The safety issue has also been addressed in a 
number of other studies; even in patients with severe 
COPD, pre-existing arrhythmias and a Pao2 of less than 
60 mm Hg, a single dose of formoterol, 12 pg, or salmeterol, 
5Opg, did not cause significantly more arrhythmias than 
placebo (21). Concern has also been raised that long-acting 
/&-agonists may induce a mismatch between ventilation and 
perfusion, resulting in a worrying degree of oxygen 
desaturation. This was examined in a three-way cross-over 
study, which showed that salmeterol, ipratropium bromide 
and salbutamol all induced an equally small and transient 
fall in Paoz (22). 
Effect on exacerbations of COPD 
Another important outcome measure in the long-term 
management of COPD is the exacerbation rate. A large 
number of exacerbations are attributed to infectious 
organisms. The exact pathophysiological mechanisms lead- 
ing to these exacerbations are not fully understood, but in 
current hypotheses, an important role has been attributed 
to the neutrophil. Histology of the small airways, as well as 
analysis of bronchoalveolar lavage fluid and sputum, has 
clearly shown an increased neutrophil load in the airways of 
patients with COPD (23,24). In addition, a correlation 
between the number of neutrophils and the severity of the 
disease has been observed (25). The neutrophils appear to 
be activated, and release a variety of mediators and 
enzymes, including serine proteinases, such as cathepsin 
G, proteinase 3 and elastase, as well as matrix metallopro- 
teinases. If the release of these proteinases exceeds the local 
neutralizing capacity of antiproteinases (ccl-antitrypsine, 
SLPI, elafin and a2-macroglobulin), the overall effect is 
epithelial damage and increased mucus production, result- 
ing in a decrease in mucociliary clearance (26). In addition, 
proteinases cleave immunoglobulins and complement 
receptors on neutrophils, leading to reduced opsonopha- 
gocytosis. These various effects facilitate bacterial coloniza- 
tion of the mucosa, which in turn further increases 
susceptibility to infection as bacteria produce ciliotoxins 
(e.g. pyocyanin and IgA proteases) that cause additional 
epithelial damage. This vicious circle facilitates bacterial 
growth and ultimately results in infection of the lower 
airways, causing an acute inflammatory process that 
produces the clinical characteristics of an exacerbation (27). 
In vitro studies have shown that P2-agonists can reduce 
the chemotactic response of neutrophils to agents such as 
endotoxin without inhibiting their antibacterial activity 
(28). In addition, very elegant studies of epithelial cell 
cultures have illustrated that long-acting inhaled b2- 
agonists can reduce the epithelial damage caused by 
bacterial toxins (e.g. pyocyanin released by Pseudomonas 
spp.) (29). If these in-vitro observations can be extrapolated 
to the situation in COPD, long-acting inhaled &agonists 
could interfere with the vicious circle underlying exacerbations, 
and thus have an important effect on the clinical outcome 
of the disease. Moreover, biopsy studies indicate that 
COPD exacerbations are associated with an increase in the 
number of eosinophils in the airways (30). To what extent 
these cells contribute to the mechanisms underlying 
exacerbations is not fully understood. Formoterol has been 
shown to inhibit mediator release from eosinophils in vitro 
(31). Furthermore, formoterol as monotherapy in asthma 
significantly reduced airway eosinophilia in patients who 
showed pronounced airway inflammation (defined as > 10 
eosinophils/mm’ of biopsy tissue) at the start of the study 
(32). Whether this also occurs in COPD is unknown, but it 
could be another mechanism by which formoterol affects 
the exacerbation rate. 
Large scale, long-term studies to evaluate the exacerba- 
tion rates in patients treated with long-acting inhaled /Jz- 
agonists as monotherapy have not yet been performed, and 
the data currently available are relatively limited. In the 
study by Boyd et al., treatment with salmeterol for 4 
months in addition to existing treatment had no significant 
effect on the number of exacerbations (7). In a recent study 
by Mahler et al., 411 patients were treated with ipratro- 
pium, 40 pg q.i.d., salmeterol, 50 pg b.i.d., or placebo for 12 
weeks (33). Ipratropium had no effect on the exacerbation 
rate, confirming the results from the much larger scale Lung 
Health Study (34), but a significant increase in the time to 
the first exacerbation was observed in the salmeterol-treated 
group. As a result, the number of patients completing the 
study without exacerbations was significantly higher than in 
the placebo or ipratropium bromide groups. Recently, 
formoterol, 12 pg b.i.d. for 12 weeks, was reported to result 
in a significant reduction in the number of ‘bad days’, 
defined as an increase in symptoms and/or decrease in peak 
flow compared with placebo or ipratropium bromide, 40 pg 
q.i.d. (12). 
Another interesting possibility in this respect is whether, 
in vitro, long-acting inhaled &-agonists and inhaled steroids 
act synergistically in their protective effect against bacterial 
colonization of airway epithelium (35). Long-term treat- 
ment with inhaled steroids in symptomatic COPD is known 
to reduce the number of exacerbations (36). It would 
therefore seem pertinent to evaluate, in a long-term study, 
whether the combination of a long-acting &agonist and an 
inhaled steroid has an additional effect on this important 
aspect of the disease. Such a study would also enable the 
effect of long-acting &agonists on the natural history of 
COPD to be elucidated. A characteristic feature of COPD 
is an accelerated decline in FEVi (37). This is not influenced 
by chronic treatment with anticholinergic agents or inhaled 
steroids (3839). To date, the effect of long-acting /&agonists 
on this aspect of the disease is unknown. 
Effect of combined treatment with a 
long-acting &agonist and an 
anticholinergic agent 
Based on the analysis of outcome measures described 
above, long-acting inhaled Pz-agonists given as monother- 
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apy appear to be at least as effective as anticholinergics, but 
with the obvious advantage of twice daily dosing. Previous 
studies have shown that a combination of anticholinergics 
and short-acting p2-agonists scores better on a number of 
outcome measures than either treatment alone (40,41). 
Similarly, in a single-dose study, formoterol given in 
addition to ipratropium bromide had additional broncho- 
dilator effect (42). What remains to be determined is 
whether the added effect of long-acting inhaled &agonists 
and anticholinergics is also reflected in longer-term clinical 
outcome measures. Preliminary data indicate that the 
combination of salmeterol, 50 pg b.i.d., with ipratropium 
bromide, 4Opg q.i.d., leads to a significantly greater 
improvement in FEVr and symptoms than either treatment 
alone (43). Again, these data need to be confirmed in larger 
trials, possibly including long-acting inhaled anticholinergic 
agents that are currently being developed (44). 
Conclusions 
Current COPD guidelines recommend a step-wise approach 
to the use of bronchodilators (45,46). In patients with mild 
COPD, short-acting inhaled &agonists and/or anticholi- 
nergics are to be used as needed, whereas in moderate and 
severe forms of the disease, maintenance treatment with the 
combination is advocated. In more severe disease, a trial in 
which theophylline is added seems worthwhile. 
Current evidence indicates that long-acting &agonists 
are clinically beneficial in the treatment of COPD. It is 
therefore not inconceivable that, in the future, long-acting 
&agonists may become the preferred form of maintenance 
treatment, possibly in combination with anticholinergic 
agents, for patients requiring short-acting inhaled b2- 
agonists frequently, as well as for those with moderate 
and severe forms of the disease. 
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